影像科学与光化学 ›› 2022, Vol. 40 ›› Issue (6): 1481-1485.DOI: 10.7517/issn.1674-0475.220603

• 综述与论文 • 上一篇    下一篇

HR-HPV基因联合TV-CDFI在宫颈癌筛查及诊断中的应用

程明艳1, 姜浩1, 孙亚男2, 王艳春3, 杨涛1, 梅艳芳4, 杜建文5, 王晶华1   

  1. 1. 承德市中心医院检验科, 河北 承德 067000;
    2. 承德市中心医院妇科, 河北 承德 067000;
    3. 承德市中心医院心内二科, 河北 承德 067000;
    4. 承德市中心医院生殖医学科, 河北 承德 067000;
    5. 承德市中心医院超声科, 河北 承德 067000
  • 收稿日期:2022-06-23 出版日期:2022-11-23 发布日期:2022-11-15
  • 通讯作者: 王晶华

Application of HR-HPV Gene Combined with TV-CDFI in Cervical Cancer Screening and Diagnosis

CHENG Mingyan1, JIANG Hao1, SUN Yanan2, WANG Yanchun3, YANG Tao1, MEI Yanfang4, DU Jianwen5, WANG Jinghua1   

  1. 1. Department of Laboratory, Chengde Central Hospital, Chengde 067000, Hebei, P. R. China;
    2. Department of Gynecology, Chengde Central Hospital, Chengde 067000, Hebei, P. R. China;
    3. Department of Cardiology, Chengde Central Hospital, Chengde 067000, Hebei, P. R. China;
    4. Department of Reproductive Medicine, Chengde Central Hospital, Chengde 067000, Hebei, P. R. China;
    5. Department of Ultrasound, Chengde Central Hospital, Chengde 067000, Hebei, P. R. China
  • Received:2022-06-23 Online:2022-11-23 Published:2022-11-15

摘要: 本研究探讨高危人乳头瘤病毒(HR-HPV)基因检查联合经阴道彩色多普勒超声(TV-CDFI)在宫颈癌筛查及诊断中的应用价值。选取84例宫颈癌患者(宫颈癌组)、100例宫颈上皮瘤变患者(CIN组)、100例宫颈炎患者(炎性组),三组患者采用HPV E6/E7 mRNA检测法、第二代杂交捕获(HC2)技术法检测宫颈组织中HPV感染阳性率,以病理学结果作为金标准分析两种方法鉴别诊断宫颈癌与宫颈上皮瘤变的价值;采用TV-CDFI检测宫颈癌Adler分级。结果显示,HPV E6/E7 mRNA检测法鉴别诊断宫颈癌与CIN患者的灵敏度为95.24%、特异度为20.00%;HC2法鉴别诊断宫颈癌与CIN患者的灵敏度为97.62%、特异度为17.00%;HPV E6/E7 mRNA检测法鉴别诊断宫颈癌与宫颈炎患者的灵敏度为95.24%、特异度为89.00%;HC2法鉴别诊断宫颈癌与宫颈炎患者的灵敏度为97.62%、特异度为92.00%。HPV E6/E7 mRNA检测法、HC2法鉴别诊断宫颈炎与宫颈癌方面具有较高的临床价值,TV-CDFI检测宫颈癌Adler分级与疾病进展关系密切,因此,宫颈癌筛查时将HR-HPV检测与TV-CDFI联合应用具有较高的临床应用价值。

关键词: 高危人乳头瘤病毒, 经阴道彩色多普勒超声, 宫颈癌, 筛查, 诊断

Abstract: This study investigated the application value of high-risk human papillomavirus (HR-HPV) genetic testing combined with transvaginal color Doppler ultrasonography (TV-CDFI) in cervical cancer screening and diagnosis. 84 patients with cervical cancer (cervical cancer group), 100 patients with cervical epithelial neoplasia (CIN group), and 100 patients with cervicitis (inflammatory group) were selected. Three groups of patients were detected by HPV E6/E7 mRNA detection method and second-generation hybrid capture technology (HC2) method to detect the positive rate of HPV infection in cervical tissue, and pathological results were regarded as the gold standard to analyze the two methods to differentially diagnose cervical cancer and cervical epithelial tumor changing value. Detected the cervical cancer adler grade by TV-CDFI. The results showed that the sensitivity and specificity of HPV E6/E7 mRNA detection in the differential diagnosis of cervical cancer and CIN patients were 95.24% and 20.00%, respectively. The sensitivity and specificity of HC2 method in the differential diagnosis of cervical cancer and CIN patients were 97.62% and 17.00%, respectively. The sensitivity and specificity of HPV E6/E7 mRNA detection in the differential diagnosis of cervical cancer and cervicitis were 95.24% and 89.00%. The sensitivity and specificity of HC2 method in the differential diagnosis of cervical cancer and cervicitis were 97.62% and 92.00%. HPV E6/E7 mRNA detection method and HC2 method have high clinical value in the differential diagnosis of cervicitis and cervical cancer. TV-CDFI detection of cervical cancer Adler grading is closely related to disease progression, therefore, the combination of HR-HPV detection and TV-CDFI in cervical cancer screening has high clinical value.

Key words: high-risk human papillomavirus, transvaginal color Doppler ultrasound, cervical cancer, screening, diagnosis